Efficacy and safety of Shengjiang Xiexin decoction on irinotecan-induced diarrhea in small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial

SXD had a prophylactic effect in the diarrhea induced by irinotecan, especially for UGT1A1 high-risk population, and this effect from SXD appeared to be maintained the completion of chemotherapy schedule. The mechanism of action of SXD was related to the regulation of inflammatory factors. Trial registration Chinese Clinical Trial Register: ChiCTR1800018490. Registered on 20 September 2018. https://www.chictr.org.cn/showproj.html?proj=25250 . The preliminary protocol of this clinical study has been published in the journal "Trials" in the form of protocol before this paper (Deng et al. in Trials 21:370, 2020).

Authors

Institutions

Publication Details

Journal
Chinese Medicine
Published
2024-11-04
DOI
https://doi.org/10.1186/s13020-024-01025-6
Citations
3
Primary Topic
Cancer therapeutics and mechanisms
Type
article
Field-Weighted Citation Impact
0.70

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of Shengjiang Xiexin decoction on irinotecan-induced diarrhea in small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial

Shijie Zhu, Huijuan Cui, Guowang Yang, Yu Gao et al.
3 citations
Chinese Medicine
Cancer therapeutics and mechanisms
0.70
article

Efficacy and safety of Shengjiang Xiexin decoction on irinotecan-induced diarrhea in small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial

Shijie Zhu, Huijuan Cui, Guowang Yang, Yu Gao, Zhiguo Zhang, Chao Deng, Qin Li, Liqun Jia, Meng Yang, Yang Ge, Y.-Q. Lou, Qing Liu
article en
3 citations

Abstract

SXD had a prophylactic effect in the diarrhea induced by irinotecan, especially for UGT1A1 high-risk population, and this effect from SXD appeared to be maintained the completion of chemotherapy schedule. The mechanism of action of SXD was related to the regulation of inflammatory factors. Trial registration Chinese Clinical Trial Register: ChiCTR1800018490. Registered on 20 September 2018. https://www.chictr.org.cn/showproj.html?proj=25250 . The preliminary protocol of this clinical study has been published in the journal "Trials" in the form of protocol before this paper (Deng et al. in Trials 21:370, 2020).

Chinese MedicineVol. 19(1)
Capital Medical University (CN), Peking University (CN), Beijing Chao-Yang Hospital, Capital Medical University (CN), China-Japan Friendship Hospital (CN), Wangjing Hospital of China Academy of Chinese Medical Sciences (CN), Peking University Third Hospital (CN), Beijing Friendship Hospital (CN), Beijing Hospital of Traditional Chinese Medicine (CN)
National Natural Science Foundation of China, China-Japan Friendship Hospital
Good health and well-being
Openalex Percentile: Top 29%
Cancer therapeutics and mechanisms
0.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.